| Patient | Barbara Jordan |
|---|---|
| Date of birth | 1936-02-21 |
| Identifiers | MRN HR-ML030-SYN-TD; SSN (made up) 000-30-6852 |
| Document date | 2026-11-01 |
| Author | Evangeline Moss, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing primary care for multiple sclerosis diagnosed elsewhere: walking, spasticity, bladder, fatigue and heat sensitivity, work, bone health, mood, and the work-up and screening before any disease-modifying therapy. Concerns: She wants to keep teaching and speaking without her health becoming the subject; She wants to know whether any treatment can slow the disease; She wants to stay safe on her feet and to have energy left at the end of a teaching day. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Cholecalciferol (vitamin D3) 1954 units (50 mcg) oral capsule, one capsule daily | One capsule daily | Oral route | 1980-03-02 | active | S |
| Baclofen 5 mg oral tablet, one tablet three times a day, to be increased to 10 mg three times a day once tolerated | One tablet three times a day | Oral route | 1980-03-16 to 1980-04-20 | completed | S |
| Baclofen 10 mg oral tablet, one tablet three times a day | One tablet three times a day | Oral route | 1980-04-20 | active | S |
| Mirabegron 25 mg extended-release oral tablet, one tablet daily | One tablet daily | Oral route | 1980-03-16 | active | S |
| Ocrelizumab 300 mg intravenous infusion on day 1 and day 15, then 600 mg every 6 months, after methylprednisolone 100 mg intravenously, an antihistamine and acetaminophen, in the infusion center | 300 mg on day 1 and day 15 (given), then 600 mg every 6 months | Intravenous route | 1980-05-04 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Bladder scan for post-void residual volume | 1980-03-02 to 1980-03-02 | completed | S |
| MRI of the brain with and without gadolinium (3D T2-FLAIR, T2, and T1 before and after contrast) | 1980-03-16 to 1980-03-16 | completed | S |
| MRI of the cervical and thoracic spine with and without gadolinium | 1980-03-16 to 1980-03-16 | completed | S |
| Ocrelizumab 300 mg intravenous infusion (first half-dose) after premedication, with observation for at least one hour afterwards | 1980-05-04 to 1980-05-04 | completed | S |
| Ocrelizumab 300 mg intravenous infusion (second half-dose) after premedication, with observation for at least one hour afterwards | 1980-05-18 to 1980-05-18 | completed | S |
| MRI of the brain without gadolinium (re-baseline on therapy) | 1980-10-26 to 1980-10-26 | completed | S |
| Dual-energy X-ray absorptiometry (DXA) of the lumbar spine and hip | 1980-08-17 to 1980-08-17 | completed | S |
| Advance care planning conversation, about 20 minutes | 1980-08-17 to 1980-08-17 | completed | S |
| Screening mammogram, both breasts | 1980-08-31 to 1980-08-31 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1980-03-16 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 1980-03-16 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
| 1980-03-16 | Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) | completed | S |
| 1980-03-16 | Hepatitis B vaccine (HepB-CpG), dose 1 of 2 | completed | S |
| 1980-04-20 | Hepatitis B vaccine (HepB-CpG), dose 2 of 2 | completed | S |
| 1980-04-20 | Recombinant zoster vaccine, dose 2 of 2 | completed | S |
| 1980-10-26 | Influenza vaccine, inactivated, this season | completed | S |
| 1980-10-26 | COVID-19 vaccine, mRNA, this season | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1978 | Walking difficulty needing a cane in her last years in the House, attributed publicly at the time to a knee problem | D (CLM-0005) |
| 1979 | Multiple sclerosis diagnosed around the time she left Congress, as later revealed; records of that evaluation are not available to this clinic | D (CLM-0006) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| She wants to keep teaching and speaking without her health becoming the subject | active | S |
| She wants to know whether any treatment can slow the disease | active | S |
| She wants to stay safe on her feet and to have energy left at the end of a teaching day | active | S |
Most recent measures: Leukocytes [#/volume] in Blood by Automated count 6.1 on 1980-10-26; Lymphocytes [#/volume] in Blood by Automated count 1.5 on 1980-10-26; Hemoglobin [Mass/volume] in Blood 13.5 on 1980-10-26; Platelets [#/volume] in Blood by Automated count 255 on 1980-10-26; Creatinine [Mass/volume] in Serum or Plasma 0.8 on 1980-10-26; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1975)/1.73 sq M 93 on 1980-10-26; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 19 on 1980-10-26; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 on 1980-10-26; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 72 on 1980-03-02; Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 on 1980-03-02; Thyrotropin [Units/volume] in Serum or Plasma 1.8 on 1980-03-02; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 520 on 1980-03-02; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 34 on 1980-06-29; IgG [Mass/volume] in Serum or Plasma 1010 on 1980-10-26; IgM [Mass/volume] in Serum or Plasma 72 on 1980-10-26; IgA [Mass/volume] in Serum or Plasma 210 on 1980-03-02; JC virus Ab Index in Serum or Plasma by Immunoassay 0.14 on 1980-03-02; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 1980-06-29; CD19 cells [#/volume] in Blood 3 on 1980-06-29; Hemoglobin A1c/Hemoglobin.total in Blood 5.4 on 1980-08-17; Cholesterol [Mass/volume] in Serum or Plasma 186 on 1980-08-17; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 110 on 1980-08-17; Cholesterol in HDL [Mass/volume] in Serum or Plasma 56 on 1980-08-17; Triglyceride [Mass/volume] in Serum or Plasma 98 on 1980-08-17; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1980-08-17 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Multiple sclerosis diagnosed elsewhere, by her account, with records of the original evaluation not available: slowly worsening walking over the past few years, leg stiffness, fatigue, urinary urgency and heat sensitivity; uses a cane; course to be classified after MRI of the brain and spine | resolved | confirmed | G35.D | S — Synthetic presenting picture at intake, superseded by the classified diagnosis at the consultation; the cane and a diagnosis around the time she left Congress are from public accounts. |
| Active primary progressive multiple sclerosis: gradual worsening of walking over more than a year without relapses, with brain lesions in periventricular, juxtacortical and infratentorial regions, three spinal cord lesions, and one gadolinium-enhancing lesion; fulfils the 1971 McDonald criteria for primary progressive disease; EDSS 6.0; synthetic modern detail linked to her publicly reported multiple sclerosis | active | confirmed | G35.B1 | S — Synthetic course, MRI findings and disability score; the disease itself and her use of a cane are from public accounts. |
| Spastic gait from multiple sclerosis, walking with a cane, with two near-falls and no falls in the past year; at risk of falls | active | confirmed | R26.89 | S — Synthetic modern coding anchored to her documented cane. |
| Neurogenic bladder from multiple sclerosis: urgency and getting up twice at night, with a low post-void residual | active | confirmed | N31.9 | S — Synthetic; common in multiple sclerosis. No public source describes her bladder. |
| Vitamin D deficiency | active | confirmed | E55.9 | S — Synthetic laboratory finding at intake. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1980-03-02 | Leukocytes [#/volume] in Blood by Automated count | 6.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1980-03-02 | Lymphocytes [#/volume] in Blood by Automated count | 1.9 | 10*3/uL | 1-4.8 10*3/uL | Normal | S |
| 1980-03-02 | Hemoglobin [Mass/volume] in Blood | 13.2 | g/dL | 12-15.5 g/dL | Normal | S |
| 1980-03-02 | Platelets [#/volume] in Blood by Automated count | 262 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1980-03-02 | Creatinine [Mass/volume] in Serum or Plasma | 0.78 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1980-03-02 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1975)/1.73 sq M | 96 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1980-03-02 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | 7-35 U/L | Normal | S |
| 1980-03-02 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | 10-35 U/L | Normal | S |
| 1980-03-02 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 72 | U/L | 35-105 U/L | Normal | S |
| 1980-03-02 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.2-1.2 mg/dL | Normal | S |
| 1980-03-02 | Thyrotropin [Units/volume] in Serum or Plasma | 1.8 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 1980-03-02 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 520 | pg/mL | 232-1245 pg/mL | Normal | S |
| 1980-03-02 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 17 | ng/mL | 30-100 ng/mL | Low | S |
| 1980-03-02 | IgG [Mass/volume] in Serum or Plasma | 1080 | mg/dL | 700-1600 mg/dL | Normal | S |
| 1980-03-02 | IgM [Mass/volume] in Serum or Plasma | 110 | mg/dL | 40-230 mg/dL | Normal | S |
| 1980-03-02 | IgA [Mass/volume] in Serum or Plasma | 210 | mg/dL | 70-400 mg/dL | Normal | S |
| 1980-03-02 | JC virus Ab Index in Serum or Plasma by Immunoassay | 0.14 | {index} | Below 0.20 negative; 0.20 to 0.40 indeterminate; above 0.40 positive | Normal | S |
| 1980-03-02 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 1980-06-29 | Leukocytes [#/volume] in Blood by Automated count | 5.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1980-06-29 | Lymphocytes [#/volume] in Blood by Automated count | 1.4 | 10*3/uL | 1-4.8 10*3/uL | Normal | S |
| 1980-06-29 | Hemoglobin [Mass/volume] in Blood | 13.4 | g/dL | 12-15.5 g/dL | Normal | S |
| 1980-06-29 | Platelets [#/volume] in Blood by Automated count | 248 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1980-06-29 | CD19 cells [#/volume] in Blood | 3 | /uL | Expected to be depleted after an anti-CD20 therapy | Low | S |
| 1980-06-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | 7-35 U/L | Normal | S |
| 1980-06-29 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 | ng/mL | 30-100 ng/mL | Normal | S |
| 1980-06-29 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 1980-08-17 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.4 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes | Normal | S |
| 1980-08-17 | Cholesterol [Mass/volume] in Serum or Plasma | 186 | mg/dL | <=199 mg/dL | Normal | S |
| 1980-08-17 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 110 | mg/dL | <=129 mg/dL | Normal | S |
| 1980-08-17 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 56 | mg/dL | >=50 mg/dL | Normal | S |
| 1980-08-17 | Triglyceride [Mass/volume] in Serum or Plasma | 98 | mg/dL | <=149 mg/dL | Normal | S |
| 1980-10-26 | Leukocytes [#/volume] in Blood by Automated count | 6.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1980-10-26 | Lymphocytes [#/volume] in Blood by Automated count | 1.5 | 10*3/uL | 1-4.8 10*3/uL | Normal | S |
| 1980-10-26 | Hemoglobin [Mass/volume] in Blood | 13.5 | g/dL | 12-15.5 g/dL | Normal | S |
| 1980-10-26 | Platelets [#/volume] in Blood by Automated count | 255 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1980-10-26 | IgG [Mass/volume] in Serum or Plasma | 1010 | mg/dL | 700-1600 mg/dL | Normal | S |
| 1980-10-26 | IgM [Mass/volume] in Serum or Plasma | 72 | mg/dL | 40-230 mg/dL | Normal | S |
| 1980-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1980-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1975)/1.73 sq M | 93 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1980-10-26 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 | U/L | 7-35 U/L | Normal | S |
| 1980-10-26 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 10-35 U/L | Normal | S |
| 1980-08-17 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1980-03-02 | Body height | 173 | cm | S |
| 1980-03-02 | Body weight | 84 | kg | S |
| 1980-03-02 | Body mass index (BMI) [Ratio] | 28.1 | kg/m2 | S |
| 1980-03-02 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1980-03-02 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1980-03-02 | Heart rate | 76 | /min | S |
| 1980-03-02 | Respiratory rate | 16 | /min | S |
| 1980-03-02 | Body temperature | 36.7 | Cel | S |
| 1980-03-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1980-03-16 | Body height | 173 | cm | S |
| 1980-03-16 | Body weight | 84.2 | kg | S |
| 1980-03-16 | Body mass index (BMI) [Ratio] | 28.1 | kg/m2 | S |
| 1980-03-16 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1980-03-16 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1980-03-16 | Heart rate | 74 | /min | S |
| 1980-03-16 | Respiratory rate | 16 | /min | S |
| 1980-03-16 | Body temperature | 36.6 | Cel | S |
| 1980-03-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1980-04-20 | Body height | 173 | cm | S |
| 1980-04-20 | Body weight | 83.8 | kg | S |
| 1980-04-20 | Body mass index (BMI) [Ratio] | 28 | kg/m2 | S |
| 1980-04-20 | Systolic blood pressure | 120 | mm[Hg] | S |
| 1980-04-20 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1980-04-20 | Heart rate | 72 | /min | S |
| 1980-04-20 | Respiratory rate | 16 | /min | S |
| 1980-04-20 | Body temperature | 36.6 | Cel | S |
| 1980-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1980-06-29 | Body height | 173 | cm | S |
| 1980-06-29 | Body weight | 83.5 | kg | S |
| 1980-06-29 | Body mass index (BMI) [Ratio] | 27.9 | kg/m2 | S |
| 1980-06-29 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1980-06-29 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1980-06-29 | Heart rate | 74 | /min | S |
| 1980-06-29 | Respiratory rate | 16 | /min | S |
| 1980-06-29 | Body temperature | 36.8 | Cel | S |
| 1980-06-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1980-10-26 | Body height | 173 | cm | S |
| 1980-10-26 | Body weight | 83.2 | kg | S |
| 1980-10-26 | Body mass index (BMI) [Ratio] | 27.8 | kg/m2 | S |
| 1980-10-26 | Systolic blood pressure | 120 | mm[Hg] | S |
| 1980-10-26 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1980-10-26 | Heart rate | 72 | /min | S |
| 1980-10-26 | Respiratory rate | 16 | /min | S |
| 1980-10-26 | Body temperature | 36.6 | Cel | S |
| 1980-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1980-08-17 | Body height | 173 | cm | S |
| 1980-08-17 | Body weight | 83.4 | kg | S |
| 1980-08-17 | Body mass index (BMI) [Ratio] | 27.9 | kg/m2 | S |
| 1980-08-17 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1980-08-17 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1980-08-17 | Heart rate | 74 | /min | S |
| 1980-08-17 | Respiratory rate | 16 | /min | S |
| 1980-08-17 | Body temperature | 36.7 | Cel | S |
| 1980-08-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1980-03-02 | Establishing primary care for multiple sclerosis diagnosed elsewhere: walking, spasticity, bladder, fatigue and heat sensitivity, work, bone health, mood, and the work-up and screening before any disease-modifying therapy | finished | S |
| 1980-03-16 | Two-week review with MRI of the brain and spine and the neurology (multiple sclerosis) consultation; vaccines before therapy | finished | S |
| 1980-04-20 | Five-week review: second vaccine doses, baclofen titration, physical therapy and readiness for the first infusion | finished | S |
| 1980-06-29 | Four-month review, six weeks after the first ocrelizumab doses: infusion tolerance, infections, blood counts, vitamin D, heat and mood | finished | S |
| 1980-10-26 | Eight-month review before the first full ocrelizumab dose: re-baseline brain MRI, blood counts and immunoglobulins, seasonal vaccines, mobility and work | finished | S |
| 1980-08-17 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Confirm and classify the diagnosis: MRI of the brain and the cervical and thoracic spine with gadolinium to the MAGNIMS-CMSC-NAIMS protocol, read against the 1971 McDonald criteria; exclude mimics with vitamin B12, TSH and HIV; request the records of the original evaluation | completed | GL-MCDONALD-2017, GL-MAGNIMS-2021 | S |
| Neurology (multiple sclerosis) consultation to confirm and classify the disease and advise on disease-modifying therapy, its monitoring, vaccination, symptom care and MRI follow-up | completed | GL-AAN-DMT-2018, GL-MCDONALD-2017, GL-MAGNIMS-2021 | S |
| Screening before any disease-modifying therapy: hepatitis B surface antigen, core antibody and surface antibody; quantitative immunoglobulins; liver tests; blood count with lymphocytes; varicella and measles immunity; tuberculosis blood test; HIV and hepatitis C; JC virus antibody; and vaccines brought up to date, inactivated vaccines at least two weeks and live vaccines at least four weeks before the first dose | completed | GL-AAN-DMT-2018, GL-AAN-VAX-2019, GL-CDC-IMZ-2026 | S |
| Relapse and pseudo-relapse plan: new or worsening symptoms lasting more than 24 hours without fever or heat mean a same-day call; check for urinary infection and fever first, because infection and heat can bring back old symptoms; written card for her bag | completed | GL-AAN-DMT-2018, GL-NICE-MS-2022 | S |
| Mobility, spasticity and falls: physical therapy evaluation for gait, strengthening, stretching, balance and a home exercise program; review of walking aids, with forearm crutches or a rollator and a scooter for long distances when she wants them; home safety review; daily stretching | completed | GL-NICE-MS-2022, GL-CMID-2026 | S |
| Bladder: post-void residual today, timed voiding, fluids earlier in the day, less caffeine, pelvic floor exercises, and a medicine if urgency persists; urine check for any burning, fever or sudden worsening | completed | GL-NICE-MS-2022 | S |
| Fatigue and heat sensitivity: energy conservation and pacing with an occupational therapy review, teaching sessions placed in the morning where she chooses, cooling garments, air conditioning, cool drinks, and aerobic exercise such as pool exercise in cool water | completed | GL-NICE-MS-2022 | S |
| Work: a letter to her employer, with her consent, describing her functional needs (an accessible teaching room near an elevator, a chair and lectern for lectures, reserved parking near her building, and flexibility for medical appointments) without naming the diagnosis; she decides what to disclose | completed | GL-JAN-MS, GL-ADA | S |
| Bone health: vitamin D3 with a recheck, calcium from food, weight-bearing exercise, fall prevention, and bone density at the preventive visit because of reduced mobility and earlier steroid courses | completed | GL-CMID-2026, GL-NICE-MS-2022 | S |
| Mood and cognition: PHQ-9 at intake and every six months; ask about concentration and word-finding; counseling offered at any time | completed | GL-USPSTF-DEP-2023, GL-NICE-MS-2022, GL-CMID-2026 | S |
| On the consultant's advice: ocrelizumab 300 mg on day 1 and day 15 and then 600 mg every 6 months, after the vaccines and at least two weeks after the last inactivated dose, with premedication and observation; blood count and immunoglobulins before each dose; a re-baseline brain MRI three to six months after the first dose and then yearly; baclofen titrated to 10 mg three times a day; mirabegron with a blood pressure check at each visit | completed | GL-AAN-DMT-2018, GL-OCR-LABEL, GL-MAGNIMS-2021, GL-NICE-MS-2022 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Diagnosis confirmed and classified, vaccines completed at least two weeks before therapy, and a disease-modifying therapy started within ten weeks | 1980-06-29 | completed | Primary progressive disease confirmed at two weeks; vaccines finished at five weeks; ocrelizumab started at nine weeks | S |
| No falls through eight months | 1980-10-26 | completed | No falls; one near-fall in the summer heat | S |
| 25-hydroxyvitamin D at least 30 ng/mL within four months | 1980-06-29 | completed | 34 ng/mL at four months | S |
| Up no more than once a night to pass urine within three months | 1980-06-29 | completed | Once a night or less on mirabegron | S |
| Keep her full teaching and speaking schedule with the accommodations she chooses | 1980-10-26 | completed | Full schedule kept; accessible rooms, seating and parking in place | S |
| No new or enlarging T2 lesions on the re-baseline MRI | 1980-10-26 | completed | No new or enlarging T2 lesions | S |